Bambi Nyanguile, S.-M., Hanson, J., OOMS, A., Alpan, L., Kolh, P., dogné, J.-M., & Pirotte, B. (July 2013). Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists. European Journal of Medicinal Chemistry, 65, 32-40. doi:10.1016/j.ejmech.2013.04.033 Peer Reviewed verified by ORBi |
Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., michiels, C., Pirotte, B., Mullier, F., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 INHIBITS THE EARLY ATHEROSCLEROTIC LESIONS IN APO-E DEFICIENT MICE BY BLOCKING TP RECEPTORS AND THROMBOXANE SYNTHASE. In Congress of the International Society of Thrombosis and Hemostasis- 57th Annual SSC Meeting. Peer reviewed |
Cherdon, C., Rolin, S., Hanson, J., OOMS, A., de Leval, L., Drion, P., Michiels, C., Pirotte, B., Masereel, B., SakalihasanN, N., DEFRAIGNE, J., & Dogné, J.-M. (2011). BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators. doi:10.1016/j.prostaglandins.2011.03.001 Peer Reviewed verified by ORBi |
Cherdon, C., Rolin, S., de Leval, L., Drion, P., Defraigne, J.-O., Ooms, A., & Dogné, J.-M. (01 December 2009). The use of an adapted model allows contributing to the “Reduction” of mice used in experimental protocols: the case of the apoE–deficient (apo E-/-) mice in a model of atherosclerosis control [Poster presentation]. Belgian Council for Animal Science Symposium, Blankenberge, Belgium. |
Cherdon, C., Rolin, S., Ooms, A., de Leval, L., Drion, P., Defraigne, J.-O., & Dogné, J.-M. (2009). Le bm-573, un antagoniste original du récepteur au thromboxane a2, réduit le développement des lésions athéromateuses chez des souris déficientes en apolipoprotéine e (apo e-/-) contrairement a l’aspirine [Paper presentation]. 21ème Journées Franco-Belges de Pharmaco chimie, 28 et 29 mai 2009, , Belgique, Mons, Belgium. Peer reviewed |